These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 22310591

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.
    Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171
    [Abstract] [Full Text] [Related]

  • 3. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N.
    Transplant Proc; 2010 Nov 27; 42(9):3455-8. PubMed ID: 21094796
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.
    Fundam Clin Pharmacol; 2007 Aug 27; 21(4):427-35. PubMed ID: 17635182
    [Abstract] [Full Text] [Related]

  • 6. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
    Kim IW, Moon YJ, Ji E, Kim KI, Han N, Kim SJ, Shin WG, Ha J, Yoon JH, Lee HS, Oh JM.
    Eur J Clin Pharmacol; 2012 May 27; 68(5):657-69. PubMed ID: 22183771
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E.
    Transplant Proc; 2012 Nov 27; 44(9):2635-8. PubMed ID: 23146479
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Mar 27; 49(3):141-75. PubMed ID: 20170205
    [Abstract] [Full Text] [Related]

  • 12. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
    Miao LY, Huang CR, Hou JQ, Qian MY.
    Biopharm Drug Dispos; 2008 Jan 27; 29(1):1-5. PubMed ID: 17941052
    [Abstract] [Full Text] [Related]

  • 13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, Won DI, Kim CD.
    Transplantation; 2013 Mar 27; 95(6):828-34. PubMed ID: 23364483
    [Abstract] [Full Text] [Related]

  • 14. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov 27; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 15. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M.
    Clin Exp Nephrol; 2017 Oct 27; 21(5):787-796. PubMed ID: 28271256
    [Abstract] [Full Text] [Related]

  • 16. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
    Meng XG, Guo CX, Feng GQ, Zhao YC, Zhou BT, Han JL, Chen X, Shi Y, Shi HY, Yin JY, Peng XD, Pei Q, Zhang W, Wang G, He M, Liu M, Yang JK, Zhou HH.
    Acta Pharmacol Sin; 2012 Dec 27; 33(12):1563-70. PubMed ID: 23085740
    [Abstract] [Full Text] [Related]

  • 17. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK.
    J Clin Pharm Ther; 2011 Oct 27; 36(5):614-24. PubMed ID: 21916909
    [Abstract] [Full Text] [Related]

  • 18. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV, Saldaña-Cruz AM, Pérez-Guerrero EE, Morán-Moguel MC, Contreras-Haro B, López-de La Mora DA, Dávalos-Rodríguez IP, Marín-Medina A, Rivera-Cameras A, Balderas-Peña LA, Gómez-Ramos JJ, Cortés-Sanabria L, Salazar-Páramo M.
    Genes (Basel); 2024 Apr 16; 15(4):. PubMed ID: 38674430
    [Abstract] [Full Text] [Related]

  • 19. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.
    Int J Mol Med; 2011 Dec 16; 28(6):1093-102. PubMed ID: 21922127
    [Abstract] [Full Text] [Related]

  • 20. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients.
    Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y.
    Ther Drug Monit; 2010 Aug 16; 32(4):394-404. PubMed ID: 20526235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.